Precision Oncology Sales Boost Guardant Health Q2 Topline, Backs FY21 Outlook, Management Updates


  • After the market close on Thursday, Guardant Health Inc (NASDAQ: GH) reported Q2 revenues increased 39% Y/Y to $92.1 million, beating the consensus of $84.61 million.
  • Guardant's oncology testing revenue grew 42% to $72.6 million, driven primarily by a 54% increase in clinical testing revenue. 
  • Development services and other revenue was $19.5 million, up 27%, reflecting several companion diagnostic project milestones achieved during the quarter.
  • It reported 20,830 tests to clinical customers and 3,653 tests to biopharmaceutical customers during the quarter, increasing …

Full story available on


Please enter your comment!
Please enter your name here